VG2025 + nivolumab

VG2025 + nivolumab is a combination therapy under investigation for advanced malignant solid tumors. **VG2025** is administered via intratumoral injection and is being studied both alone and in combination with **nivolumab**, an anti-PD-1 human IgG4 monoclonal antibody immunotherapy. Nivolumab promotes antitumor immune response by blocking the programmed cell death-1 (PD-1) pathway, enhancing T-cell activity against cancer cells. The combination is being explored in a dose-escalation Phase I trial to evaluate safety, tolerability, and preliminary efficacy. Nivolumab is approved for multiple oncology indications, but VG2025 is investigational in this context[2]. The developer of VG2025 is leveraging its potential for enhancing checkpoint blockade with direct intratumoral immunomodulation.

Other names

VG2025 + nivolumab